arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

AMGEN INC

AMGN
$410.89 ▲ +5.98 (+1.48%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
74 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

AMGEN INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $221.9B
Dividend Yield 0.61%
Revenue Growth 5.8%
Op. Margin 30.9%
ROIC 3.5%
FCF / Share $2.74
Trailing P/E 121.9x
Price / Book 24.1x
FCF Yield 0.7%
Debt / Equity 6.24
info Valuation on last close. End-of-day price, Aug 7, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.62B
↑ +5.8%
Net Income Profit after all expenses
$1.82B
↑ +5.1%
Operating Margin Operating profit as % of sales
30.9%
↑ +12.2% 81th
FCF / Share Free cash flow per share
$2.74
↑ +50.2%
Long-Term Debt Long-term obligations
$57.32B
↑ +5.0%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
83
Returns
99
Financial Health
35
Cash Quality
68

Dividend History

Dividend / share · sourced from SEC filings
$9.66 Latest / share
+5.8% YoY
+28.5% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters